Abstract
In a purchase designed to boost its cardiovascular disease drug portfolio, Bristol Myers Squibb will pay $13.1 billion in cash for MyoKardia. The centerpiece of the deal is mavacamten, a treatment for a chronic heart disease that could reach the market next year. Mavacamten is an allosteric modulator of myosin, a protein in heart muscle fiber that binds to a second protein, actin, to control how the heart pumps blood. MyoKardia has been studying the compound in an inherited form of heart disease called hypertrophic cardiomyopathy (HCM), which in some people causes a blockage in the route that blood takes to exit the heart. People with HCM are prone to fatigue and shortness of breath and are at risk of stroke and heart failure. In May, MyoKardia released data from a Phase 3 trial of mavacamten that enrolled 251 people with HCM. Everyone given the drug saw an increase in
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
